Test Price
2,800 AEDโ Home Collection Available
TP63 Gene Ectrodactyly-Ectodermal Dysplasia-Cleft Lip/Palate Syndrome Type 3 (EEC3) Genetic Test
Executive Summary & Core Metrics
The TP63 gene sequencing test for EEC syndrome type 3 delivers definitive molecular diagnosis for patients presenting with ectrodactyly, ectodermal dysplasia, and cleft lip/palate. Our high-coverage next-generation sequencing platform examines all coding exons and flanking intronic regions of TP63, achieving >99.9% analytic sensitivity and specificity certified to UAE DHA standards.
- โ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing
- โ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM โ 11 PM)
- โ Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation
- โ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
The TP63 gene NGS panel provides comprehensive mutation detection for EEC syndrome type 3, utilizing high-coverage sequencing that captures single nucleotide variants, small insertions/deletions, and copy number alterations across all coding regions. Turnaround time is 3โ4 weeks from sample receipt, with a standard peripheral whole blood specimen required.
| Feature | Our NGS TP63 Test | Sanger Single-Variant Test |
|---|---|---|
| Precision | >99.9% analytic sensitivity and specificity | ~99% for known variant only |
| Method | High-coverage NGS + CNV detection | Sanger sequencing of a single mutation |
| Turnaround | 3โ4 weeks | 1โ2 weeks (limited scope) |
Physician Insight & Safety Protocols
โAs a Consultant Medical Genetics, I emphasize that definitive molecular diagnosis of EEC syndrome type 3 through TP63 sequencing is essential for accurate genetic counseling and family planning. The high-coverage NGS platform captures both single nucleotide variants and copy number changes, providing comprehensive mutation detection that guides clinical management and recurrence risk assessment. Always interpret these results alongside detailed clinical phenotyping by a qualified geneticist.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice
Important Clinical Reminder
This genetic test is a diagnostic adjunct and does not replace a comprehensive clinical evaluation by a medical geneticist. Do not discontinue prescribed medications or therapeutic interventions without consulting your supervising physician. Results should be reviewed in the context of the patientโs full clinical presentation.
Exclusion Criteria & Emergency Red Flags
- Recent blood transfusion (within 2 weeks) may introduce donor DNA interference; reschedule collection if possible until after the window.
- Confirmed or suspected TP63 mosaicism may require fibroblast culture from skin biopsy; contact our laboratory for specimen handling guidance.
- If the child develops sudden respiratory distress, cyanosis, or severe feeding difficulties, proceed to the nearest emergency department immediately. These symptoms are unrelated to the blood draw but can arise from syndromic complications requiring urgent attention.
Patient FAQ & Clinical Guidance
1. What is the TP63 Gene EEC Syndrome Type 3 DNA Test?
This test uses next-generation sequencing to detect pathogenic variants in the TP63 gene that cause EEC syndrome type 3. The condition is characterized by ectrodactyly (split-hand/foot malformation), ectodermal dysplasia (abnormal development of skin, hair, nails, and teeth), and cleft lip and/or palate. Positive results provide a molecular confirmation to guide surveillance and family planning.
2. How is the sample collected and what is the turnaround time?
A standard peripheral whole blood sample (2โ5 mL in EDTA tube) is collected via our DHA-licensed VIP mobile phlebotomy service, available daily from 8 AM to 11 PM with temperature-controlled cold-chain transport. Alternatively, a buccal swab or FTA card spot may be used for young children. Results are reported within 3โ4 weeks of sample receipt.
3. Is this genetic test covered by UAE health insurance?
Coverage varies by insurer and policy. Most UAE health insurers provide reimbursement for genetic testing of congenital anomalies when deemed medically necessary. Our team can verify your specific coverage via WhatsApp at +971 54 548 8731 prior to sample collection.
4. What clinical guidance is provided after receiving results?
Every report includes a telephonic post-test consultation with a board-certified clinical geneticist to explain findings, discuss recurrence risks, and coordinate referrals to pediatric subspecialists as needed. We also provide a written summary in Arabic and English for family distribution and medical records.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to all applicable UAE federal laws governing genetic testing and patient data. All personal health information is handled in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Test results are encrypted, access-controlled, and retained only for the period necessary for clinical care and legal compliance.
For privacy inquiries or to request data subject rights, contact our Data Protection Officer at dpo@dnalabsuae.com.
Clinical & Logistical Metadata
| Test Name | TP63 Gene Ectrodactyly-Ectodermal Dysplasia-Cleft Lip/Palate Syndrome Type 3 (EEC3) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA tube), Buccal Swab, or FTA Card |
| Methodology Used | High-Coverage Next-Generation Sequencing (NGS) with CNV Detection |
| ICD-10-CM Code | Q87.2 (Ectrodactyly-ectodermal dysplasia-cleft lip/palate syndrome) |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians